Adherence and Potency with Antiretroviral Therapy: A Combination for Success

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 2, 2003, Pages

  Gathe Jr , Joseph ^a  

^a Therapeutic Concepts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG POTENCY; DYSPHORIA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0242362778     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310012-00004     Document Type: Review

References (16)

1. Murphy R, Brun S, King M, et al. Lopinavir/ritonavir (Kaletra) in antiretroviral naïve HIV+ patients: 4-year follow-up [abstract H-165]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
2. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results [abstract 564b]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
3. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-9.
4. Raboud JM, Harris M, Rae S, et al. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002;3:118-24.
5. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3.
6. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-1.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
8. U.S. Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 2002;51(No. RR-7):1-64.
9. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl JMed 2002;346:2039-46.
10. King M, Brun S, Tschampa J, et al. Exploring the effects of adherence on resistance: use of local linear regression to reveal relationships between adherence and resistance in antiretroviral-naïve patients treated with lopinavir/ritonavir or nelfinavir [abstract]. Presented at the XII International Drug Resistance Workshop, Cabo del Sol, Mexico, June 10-14, 2003.
11. Cheever L. Forum for Collaborative HIV Research. What do we know about adherence levels in different populations? In: Adherence to HIV therapy: building a bridge to success. Report from a workshop sponsored by DHHS Health Resources and Services Administration and the Forum for HIV Research in collaboration with NIH Office of AIDS Research, Washington, DC, November 15-16, 1999: 10.
12. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
13. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [abstract 528]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001.
14. Bass D, Smith MF. HIV patients prefer once-daily regimens [abstract Mo-PeB3290]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
15. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003;36:1186-90.
16. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr 2001;28:124-31.